BLLN · BillionToOne, Inc.
Price & Indicators
The closing range uses available history since Nov 6, 2025; less than a full year is stored.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $42.17M | Six Months Ended June 30, 2026 | — |
| EBITDA | $4.66M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) 8.05M
-536K Provision for income taxes
-4.69M Interest (income)
+8K Interest expense
+1.83M Depreciation and amortization
= EBITDA 4.66M
|
|||
| Free cash flow non-GAAP | $16.05M | Six Months Ended June 30, 2026 | — |
| Gross profit margin | 70% | second quarter of 2026 | — |
|
|
|||
| Non-GAAP income (loss) from operations non-GAAP | $13.72M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Income (loss) from operations 5.5M
+8.22M Stock-based compensation expense
= Non-GAAP income (loss) from operations 13.72M
|
|||
| Non-GAAP net income (loss) non-GAAP | $19.54M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) 8.05M
+8.22M Stock-based compensation expense
+2.97M Change in fair value of term loan
+297K Change in fair value of warrant liabilities
= Non-GAAP net income (loss) 19.54M
|
|||
| Overall ASP | $561 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total test volume | 197,000 | the three months ended June 30, 2026 filing | — |
| Total tests accessioned | 386,000 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total tests delivered | 384,000 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Net cash flow, excluding the net proceeds received from the issuance of common stock in connecti non-GAAP | $12.5M | the full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLLN
this stock
BillionToOne, Inc.
|
$4.58B | +13.9% | +100.0% | — | 4.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$230.05B | +7.4% | +14.5% | 33.5 | 1.3% |
|
DHR
Danaher Corp /De/
|
$151.51B | -5.6% | +8.5% | 38.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$48.82B | +42.4% | -2.8% | — | 3.0% |
|
IQV
Iqvia Holdings Inc.
|
$43.79B | +16.1% | +41.6% | 32.6 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLLN | -1.9% | -32.7% | +29.3% | -32.7% | +13.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -2.4% | -35.7% | +15.9% | -35.7% | +1.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.